Substance Use Disorder Treatment Services in the United States

Substance use disorder (SUD) treatment in the United States spans a wide continuum — from a brief counseling session at a community health clinic to months of residential care followed by years of outpatient support. The Substance Abuse and Mental Health Services Administration (SAMHSA) estimates that approximately 46.3 million Americans met criteria for a substance use disorder in 2021, yet fewer than 1 in 4 received any form of treatment. Understanding what the treatment system actually consists of, how it connects to insurance and federal policy, and where the real decision points lie can make a meaningful difference in whether someone finds effective care — or doesn't.

Definition and scope

Substance use disorder treatment refers to the structured delivery of medical, behavioral, and social interventions designed to address compulsive substance use that causes clinically significant impairment. The diagnostic framework comes from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), which consolidates older distinctions between "abuse" and "dependence" into a single severity spectrum — mild, moderate, or severe — rated across 11 criteria including tolerance, withdrawal, and failure to fulfill major role obligations.

The treatment system in the United States is notably decentralized. Services are delivered by hospitals, freestanding residential programs, outpatient clinics, federally qualified health centers, and individual licensed practitioners. Oversight is split between federal agencies — primarily SAMHSA and the Drug Enforcement Administration (DEA) for controlled prescriptions — and state behavioral health licensing boards, which means standards vary substantially across state lines.

Federal law shapes access in important ways. The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) requires that insurance plans covering mental health and substance use disorder benefits do so at parity with medical and surgical benefits — a rule that has been extensively litigated because enforcement remains uneven. The Affordable Care Act later classified SUD treatment as one of ten essential health benefits, extending coverage requirements to individual and small-group marketplace plans.

How it works

Treatment for substance use disorder is organized along what SAMHSA calls the Continuum of Care — a model that matches intensity of services to clinical severity. That continuum has five broad levels, most directly codified in the American Society of Addiction Medicine (ASAM) Patient Placement Criteria:

1. Early intervention — Screening, brief intervention, and referral to treatment (SBIRT), typically in primary care or emergency settings, targeting individuals at risk before full disorder criteria are met.
2. Outpatient treatment — Standard outpatient services averaging fewer than 9 hours of structured programming per week, including individual therapy, group counseling, and medication management.
3. Intensive outpatient (IOP) and partial hospitalization (PHP) — 9 to 20+ hours per week of structured services, respectively, allowing patients to live at home while receiving near-daily clinical support.
4. Residential treatment — 24-hour structured care in a non-hospital setting, ranging from short-term detoxification programs (typically 3–7 days) to long-term therapeutic communities lasting 6 to 12 months.
5. Medically managed intensive inpatient — Hospital-level detoxification and stabilization for patients whose withdrawal severity or medical complexity requires round-the-clock nursing and physician oversight.

Medication-assisted treatment (MAT) — now more precisely termed medications for opioid use disorder (MOUD) for opioid cases — is integrated across multiple levels. FDA-approved medications include methadone (dispensed only through licensed opioid treatment programs), buprenorphine (prescribable by certified clinicians under the DATA 2000 waiver framework, though that waiver requirement was eliminated by the Consolidated Appropriations Act of 2023), and naltrexone (available as a monthly extended-release injectable under the brand name Vivitrol). Mental health services are routinely co-located or integrated, reflecting high rates of co-occurring psychiatric conditions in this population.

Common scenarios

The path into treatment rarely looks like a clean referral. A person experiencing opioid withdrawal arrives at an emergency department, gets stabilized with buprenorphine over 24 hours, and is ideally transferred to an outpatient MOUD provider — a handoff that works far more reliably in urban academic medical centers than in rural counties with no certified prescribers. SAMHSA's 2022 data show that only about 22% of the roughly 2 million people with opioid use disorder received any MOUD in the prior year.

Alcohol use disorder, the most prevalent SUD in the country, frequently enters the treatment system through primary care, community health centers, or employee assistance programs. Medications including naltrexone and acamprosate are FDA-approved for alcohol use disorder but remain dramatically underprescribed — a pattern documented in research published in the Journal of the American Medical Association and confirmed by SAMHSA survey data.

Adolescents represent a distinct population. Developmentally appropriate outpatient and family-based treatments differ substantially from adult models; residential placement for minors carries heightened regulatory scrutiny following sustained federal attention to unregulated "troubled teen" programs. Healthcare access and equity concerns compound treatment gaps for low-income populations, people in rural areas, and communities of color, where both coverage and provider availability lag national averages.

Decision boundaries

Choosing among treatment levels — and navigating whether a given level is covered — involves several intersecting factors. Clinical placement criteria (the ASAM levels above) provide a structured framework, but insurance authorization decisions frequently diverge from clinical recommendations. A healthcare coverage options review is often a necessary parallel step.

Key distinctions practitioners and families encounter:

• Detoxification vs. treatment: Medically supervised detox addresses acute withdrawal but does not constitute treatment for the underlying disorder. Completion of detox without follow-on care is associated with sharply elevated relapse and overdose risk.
• Residential vs. outpatient: For most individuals, research does not demonstrate superior long-term outcomes from residential over intensive outpatient care — a finding that frequently surprises families who equate more restrictive settings with more effective care.
• Peer support vs. clinical care: Peer recovery support services — provided by people with lived experience of recovery — are evidence-informed, billable under Medicaid in 47 states as of 2023 (SAMHSA peer services resource guide), and distinct from licensed clinical services, though the two work most effectively in combination.
• Voluntary vs. court-mandated treatment: Drug courts and civil commitment statutes in 37 states allow involuntary treatment under specific legal findings. Outcomes for court-involved individuals are comparable to voluntary treatment when evidence-based practices are used, according to the National Institute on Drug Abuse (NIDA).

Navigating the healthcare system for SUD care is complicated by stigma, insurance barriers, and a provider workforce that remains undersized relative to need — the healthcare workforce shortage extends acutely into addiction medicine and addiction psychiatry, two specialties with board certification pathways that are less than three decades old.